RWJ-241947 (MCC-555), a Unique Peroxisome Proliferator-Activated Receptor-γ Ligand with Antitumor Activity against Human Prostate Cancer in Vitro and in Beige/Nude/X-Linked Immunodeficient Mice and Enhancement of Apoptosis in Myeloma Cells Induced by Arsenic Trioxide

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1508-1520

  Kumagai, Takashi ^a,c   Ikezoe, Takayuki ^a   Gui, Dorina ^a   O'Kelly, James ^a   Tong, Xiang Jun ^a   Cohen, Fredric J ^b   Said, Jonathan W ^a   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Clinical Research Department   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANDROGEN; ANDROGEN RECEPTOR; ANTIDIABETIC AGENT; ARSENIC TRIOXIDE; CHOLESTEROL; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; LIGAND; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROSTATE SPECIFIC ANTIGEN; PROTEIN P21; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; FIBROSIS; GENE INACTIVATION; GIANT CELL; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MITOSIS INHIBITION; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REPORTER GENE; TECHNIQUE; TUMOR GROWTH; TUMOR XENOGRAFT;

AGAR; ANIMALS; ANTIGENS, CD36; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LIGANDS; LINKAGE (GENETICS); LUCIFERASES; MALE; MICE; MULTIPLE MYELOMA; OXIDES; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TETRAZOLIUM SALTS; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; U937 CELLS; X CHROMOSOME;

EID: 1642343741     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0476-03     Document Type: Article

References (62)

1. Tontonoz, P., Hu, E., and Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell, 79: 1147-1156, 1994.
2. Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G., Moore, K., Milstone, D. S., Spiegelman, B. M., and Mortensen, R. M. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell, 4: 611-617, 1999.
3. Ciaraldi, T. P., Gilmore, A., Olefsky, J. M., Goldberg, M., and Heidenreich, K. A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism, 39: 1056-1162, 1990.
4. Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med., 331: 1188-1193, 1994.
5. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 94: 237-241, 1997.
6. Demetri, G. D., Fletcher, C. D., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., and Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA, 96: 3951-3956, 1999.
7. Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D. S., Oh, W., Demetri, G., Figg, W. D., Zhou, X. P., Eng, C., Spiegelman, B. M., and Kantoff, P. W. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. USA, 97: 10990-10995, 2000.
8. Elstner, E., Muller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., and Koeffler, H. P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA, 95: 8806-8811, 1998.
9. Suh, N., Wang, Y., Williams, C. R., Risingsong, R., Gilmer, T., Willson, T. M., and Sporn, M. B. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res., 59: 5671-5673, 1999.
10. Mehta, R. G., Williamson, E., Patel, M. K., and Koeffler, H. P. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J. Natl. Cancer Inst. (Bethesda), 92: 418-423, 2000.
11. Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., Said, J. W., Holden, S., Miyoshi, I., and Koeffler, H. P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3344-3352, 1998.
12. Shappell, S. B., Gupta, R. A., Manning, S., Whitehead, R., Boeglin, W. E., Schneider, C., Case, T., Price, J., Jack, G. S., Wheeler, T. M., Matusik, R. J., Brash, A. R., and Dubois, R. N. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res., 61: 497-503, 2001.
13. Ohta, K., Endo, T., Haraguchi, K., Hershman, J. M., and Onaya, T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab., 86: 2170-2177, 2001.
14. Satoh, T., Toyoda, M., Hoshino, H., Monden, T., Yamada, M., Shimizu, H., Miyamoto, K., and Mori, M. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene, 21: 2171-2180, 2002.
15. Itami, A., Watanabe, G., Shimada, Y., Hashimoto, Y., Kawamura, J., Kato, M., Hosotani, R., and Imamura, M. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int. J. Cancer, 94: 370-376, 2001.
16. Goke, R., Goke, A., Goke, B., El-Deiry, W. S., and Chen, Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21wafl/cipl. Digestion, 64: 75-80, 2001.
17. Inoue, K., Kawahito, Y., Tsubouchi, Y., Kohno, M., Yoshimura, R., Yoshikawa, T., and Sano, H. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem. Biophys. Res. Commun., 287: 727-732, 2001.
18. Rumi, M. A., Sato, H., Ishihara, S., Kawashima, K., Hamamoto, S., Kazumori, H., Okuyama, T., Fukuda, R., Nagasue, N., and Kinoshita, Y. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br. J. Cancer, 84: 1640-1647, 2001.
19. Takahashi, N., Okumura, T., Motomura, W., Fujimoto, Y., Kawabata, I., and Kohgo, Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett., 455: 135-139, 1999.
20. Reginato, M. J., Bailey, S. T., Krakow, S. L., Minami, C., Ishii, S., Tanaka, H., and Lazar, M. A. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J. Biol. Chem., 273: 32679-32684, 1998.
21. Mervis, J. Ancient remedy performs new tricks. Science (Wash. DC), 273: 578, 1996.
22. Donofrio, P. D., Wilbourn, A. J., Albers, J. W., Rogers, L., Salanga, V., and Greenberg, H. S. Acute arsenic intoxication presenting as Guillain-Barre-like syndrome. Muscle Nerve, 10: 114-120, 1987.
23. Sun, H. D., Ma, L., and Hu, X. C. Arsenic trioxide treated 32 cases of acute promyelocytic leukemia. Journal of Integration of Chinese and Western Medicine, 12: 170-171, 1992.
24. Soignet, S. L., Maslak, P., Wang, Z. G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, R. P., Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339: 1341-1348, 1998.
25. Shen, Z. X., Chen, G. Q., Ni, J. H., Li, X. S., Xiong, S. M., Qiu, Q. Y., Zhu, J., Tang, W., Sun, G. L., Yang, K. Q., Chen, Y., Zhou, L., Fang, Z. W., Wang, Y. T., Ma, J., Zhang, P., Zhang, T. D., Chen, S. J., Chen, Z., and Wang, Z. Y. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89: 3354-3360, 1997.
26. Chen, G. Q., Zhu, J., Shi, X. G., Ni, J. H., Zhong, H. J., Si, G. Y., Jin, X. L., Tang, W., Li, X. S., Xong, S. M., Shen, Z. X., Sun, G. L., Ma, J., Zhang, P., Zhang, T. D., Gazin, C., Naoe, T., Chen, S. J., Wang, Z. Y., and Chen, Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 88: 1052-1061, 1996.
27. Rousselot, P., Labaume, S., Marolleau, J. P., Larghero, J., Noguera, M. H., Brouet, J. C., and Fermand, J. P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and inplasma cells from myeloma patients. Cancer Res., 59: 1041-1048, 1999.
28. Park, W. H., Seol, J. G., Kim, E. S., Hyun, J. M., Jung, C. W., Lee, C. C., Kim, B. K., and Lee, Y. Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res., 60: 3065-3671, 2000.
29. Koshiuka, K., Elstner, E., Williamson, E., Said, J. W., Tada, Y., and Koeffler, H. P. Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. Br. J. Cancer, 82: 452-458, 2000.
30. Liu, L. S., Tanaka, H., Ishii, S., and Eckel, J. The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Endocrinology, 139: 4531-4539, 1998.
31. Ikezoe, T., Miller, C. W., Kawano, S., Heaney, A., Williamson, E. A., Hisatake, J., Green, E., Hofmann, W., Taguchi, H., and Koeffler, H. P. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res., 61: 5307-5310, 2001.
32. Elstner, E., Linker-Israeli, M., Said, J., Umiel, T., de Vos, S., Shintaku, I. P., Heber, D., Binderup, L., Uskokovic, M., and Koeffler, H. P. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55: 2822-2830, 1995.
33. Pang, S., Dannull, J., Kaboo, R., Xie, Y., Tso, CL., Michel, K., deKernion, J. B., and Belldegrun, A. S. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res., 57: 495-499, 1997.
34. Abreu-Martin, M. T., Chari, A., Palladino, A. A., Craft, N. A., and Sawyers, C. L. Mitogen-activated protein kinase kinase kinase I activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol. Cell. Biol., 19: 5143-5154, 1999.
35. Huang, W., Shostak, Y., Tarr, P., Sawyers, C., and Carey, M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J. Biol. Chem., 274: 25756-25768, 1999.
36. Hisatake, J. I., Ikezoe, T., Carey, M., Holden, S., Tomoyasu, S., and Koeffler, H. P. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer. Cancer Res., 60: 5494-5498, 2000.
37. Otto, T., Rembrink, K., Goepel, M., Meyer-Schwickerath, M., and Rubben, H. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol. Res., 21: 359-362, 1993.
38. Koeffler, H. P. Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res., 9: 1-9, 2003.
39. Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A., and Evans, R. M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell, 93: 241-252, 1998.
40. Moore, K. J., Rosen, E. D., Fitzgerald, M. L., Randow, F., Andersson, L. P., Altshuler, D. Milstone, D. S., Mortensen, R. M., Spiegelman, B. M., and Freeman, M. W. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med., 7: 41-47, 2001.
41. Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., and Evans, R. M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med., 7: 48-52, 2001.
42. Ryoo, J. J., Cole, C. E., and Anderson, K. C. Novel therapies for multiple myeloma. Blood Rev., 16: 167-174, 2002.
43. Elstner, E., Linker-Israeli, M., Umiel, T., Le, J., Grillier, I., Said, J., Shintaku, I. P., Krajewski, S., Reed, J. C., Binderup, L., and Koeffler, H. P. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res., 56: 3570-3576, 1996.
44. Elstner, E., Linker-Israeli, M., Le, J., Umiel, T., Michl, P., Said, J. W., Binderup, L., Reed, J. C., and Koeffler, H. P. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. J. Clin. Investig., 99: 349-360, 1997.
45. Stio, M., Celli, A., and Treves, C. Synergistic anti-proliferative effects of vitamin D derivatives and 9-cis retinoic acid in SH-SY5Y human neuroblastoma cells. J. Steroid Biochem. Mol. Biol., 77: 213-222, 2001.
46. Danielsson, C., Torma, H., Vahlquist, A., and Carlberg, C. Positive and negative interaction of 1,25-dihydroxyvitamin D3 and the retinoid CD437 in the induction of human melanoma cell apoptosis. Int. J. Cancer, 81: 467-470, 1999.
47. Parmar, S., and Tallman, M. S. Acute promyelocytic leukaemia: a review. Exp. Opin. Pharmacother., 4: 1379-1392, 2003.
48. Joyce, D., Albanese, C., Steer, J., Fu, M., Bouzahzah, B., and Pestell, R. G. NF-kappaB and cell-cycle regulation: the cyclin connection. Rev. Cytokine Growth Factor Rev., 12: 73-90, 2001.
49. Karin, M., and Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Rev. Annu. Rev. Immunol., 18: 621-663, 2000.
50. Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., Fletcher, J. A., Hlatky, L., Hahnfeldt, P., Folkman, J., and Kaipainen, A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Investig., 110: 923-932, 2002.
51. Jozkowicz, A., Dulak, J., Piatkowska, E., Placha, W., and Dembinska-Kiec, A. Ligands of peroxisome proliferator-activated receptorgamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim. Pol., 47: 1147-1157, 2000.
52. Fauconnet, S., Lascombe, I., Chabannes, E., Adessi, G. L., Desvergne, B., Wahli, W., and Bittard, H. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J. Biol. Chem., 277: 23534-23543, 2002.
53. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (Lond.), 391: 79-82, 1998.
54. Jiang, C., Ting, A. T., and Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature (Lond.), 391: 82-86, 1998.
55. Maggi, L. B., Jr., Sadeghi, H., Weigand, C., Scarim, A. L., Heitmeier, M. R., and Corbett, J. A. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes, 49: 346-355, 2000.
56. Palakurthi, S. S., Aktas, H., Grubissich, L. M., Mortensen, R. M., and Halperin, J. A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res., 61: 6213-6218, 2001.
57. Wang, M., Wise, S. C., Leff, T., and Su, T. Z. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma. Diabetes, 48: 254-260, 1999.
58. Jaafar, R., Omar, I., Jidon, A. J., Wan-Khamizar, B. W., Siti-Aishah, B. M., and Sharifah-Noor-Akmal, S. H. Skin cancer caused by chronic arsenical poisoning-a report of three cases. Med. J. Malaysia, 48: 86-92, 1993.
59. Dong, J. T., and Luo, X. M. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat. Res., 315: 11-15, 1994.
60. Barbey, J. T. Cardiac toxicity of arsenic trioxide. Review: discussion. Blood, 98: 1633-1634, 2001.
61. Singer, J. W. Cardiac toxicity of arsenic trioxide. Discussion. Blood, 98: 1633-1634, 2001.
62. Westervelt, P., Brown, R. A., Adkins, D. R., Khoury, H., Curtin, P., Hurd, D., Luger, S. M., Ma, M. K., Ley, T. J., and DiPersio, J. F. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood, 98: 266-271, 2001.